Tranexamic Acid Injection Indications
Tranexamic acid injection is FDA-approved for hemophilia patients undergoing tooth extraction, but has strong evidence-based support for off-label use in post-partum hemorrhage (within 3 hours of birth) and trauma patients with hemorrhagic shock (within 90 minutes of injury).
FDA-Approved Indication
The only FDA-approved indication for tranexamic acid injection is:
- Hemophilia patients undergoing tooth extraction to reduce or prevent hemorrhage and decrease need for replacement therapy, used for 2-8 days 1
Evidence-Based Off-Label Indications
Post-Partum Hemorrhage (Strongest Guideline Evidence)
WHO strongly recommends intravenous tranexamic acid for treatment of post-partum hemorrhage when given within 3 hours of birth 2. This represents the most robust guideline-level evidence available.
Key parameters:
- Timing: Must be administered within 3 hours of birth (benefit decreases 10% for every 15-minute delay; potentially harmful after 3 hours)
- Definition: Clinically estimated blood loss >500 mL after vaginal birth or >1000 mL after cesarean section, or any blood loss compromising hemodynamic stability
- Dosing: 1 g IV over 10 minutes, with second 1 g dose if bleeding continues after 30 minutes or restarts within 24 hours
- Scope: Should be given for ALL cases of PPH regardless of cause (trauma, uterine atony, etc.) - this is broader than previous recommendations that limited use to refractory cases 2
Trauma with Hemorrhagic Shock
Prehospital TXA administration may reduce mortality in adult trauma patients with hemorrhagic shock when administered after lifesaving interventions 3, 4.
Critical specifications:
- Patient selection: Clinical signs of hemorrhagic shock with life-threatening hemorrhage
- Timing window: Within 90 minutes of injury is optimal (no benefit after 3 hours) 5, 3
- Dosing options: Either 1 g IV/IO (followed by 1 g infusion over 8 hours in hospital) OR 2 g IV/IO as infusion or slow push 3
- Mortality benefit: Relative risk reduction of 0.73 [0.56-0.96] when given appropriately 5
Important caveat: In trauma patients WITHOUT shock, the absolute risk difference for mortality ranges from -5% to +5%, meaning no clear benefit and potential harm 5
Isolated Traumatic Brain Injury
The evidence is inconsistent for isolated TBI - no consistent mortality benefit has been demonstrated, though there may be effects on progression of intracranial bleeding 5. This is NOT a strong indication.
Contraindications (Critical Safety Information)
Tranexamic acid is absolutely contraindicated in:
- Subarachnoid hemorrhage (may cause cerebral edema and infarction) 1
- Active intravascular clotting 1
- Hypersensitivity to tranexamic acid 1
Thromboembolic Risk Considerations
Dose-dependent thromboembolic risk exists, with marked increase at 4 g (HR 5.33 [1.94-14.63]) 5. The standard 1-2 g dosing appears safer. Avoid concomitant use with pro-thrombotic agents (Factor IX concentrates, hormonal contraceptives) 1.
Special population concern: Patients with gastrointestinal bleeding show increased risk of venous thrombosis 6, making this a questionable indication.
Pediatric Considerations
The role in pediatric trauma has not been studied and standardized dosing is not established 3. If used, it should be given within 3 hours of injury, but this represents expert opinion rather than evidence-based practice.
Administration Route Alternatives
While IV is standard, emerging evidence suggests:
- Intramuscular: 30 mg/kg IM (double the standard 15 mg/kg dose) achieves comparable serum concentrations to IV administration 7
- Intraarticular: Effective for orthopedic procedures 8
- Subcutaneous: Demonstrated efficacy in dermatologic surgery 9
These alternative routes may be valuable in austere environments or when IV access is difficult 10.